Gilead Sciences, Inc.

NASDAQ:GILD

Drug Manufacturers - General

Healthcare
$168.98 -2.14%

-$2.69 today

Market cap
$209.59B
Beta
0.33
P/E (TTM)
16.5
EPS (TTM)
$7.42
Dividend yield
2.62%
52W Low $104.46High $157.29

Volume 4.82M

Average 6.78M

GILD Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Gilead Sciences, Inc.NASDAQ: GILD

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $1.76B rose 18.3% year over year, ahead of the +2.7% change in trailing-twelve-month research & development. Sequentially, it rose 28.6% from the prior quarter. Over 3 fiscal years it compounded at +5.2% a year.

Context

  • Research & development amounted to 19.7% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +18.3% holds above the trailing-twelve-month pace of +2.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.76B+28.6% QoQ
Last fiscal yearDec 2025
$5.8B-1.8% YoY
LTMJun 2026
$6.07B+2.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.3%——
1 year-1.8%——
3-year CAGR+5.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
5.8B USD
Year-over-year change
-1.8%
4-year CAGR
+6.0%

Research & Development vs competitors

How GILD compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2.7% is the 7th highest of 10, against a peer median of +7.0%.
  • Research & development amounts to 19.9% of revenue for GILD, versus a peer median of 18.3%.
GILD Competitors
Research & Development for GILD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$28.35B USD+65.7%-2.6%42.7%
JNJJohnson & JohnsonLTM Sep 2026$16.08B USD+2.4%+1.2%16.2%
AZNAstraZeneca PLCLTM Sep 2026$15.01B USD-0.3%+13.4%24.1%
LLYEli Lilly and CompanyLTM Jun 2026$14.6B USD+23.4%+22.9%18.3%
NVSNovartis AGLTM Jun 2026$11.28B USD+9.2%+5.4%20.3%
PFEPfizer Inc.LTM Jun 2026$11.05B USD+7.0%-3.0%17.3%
ABBVAbbVie Inc.LTM Sep 2026$9.96B USD-25.0%+11.8%15.1%
GSKGSK plcLTM Jun 2026£9.2B GBP+31.8%+11.1%27.7%
SNYSanofiLTM Jun 2026€8.11B EUR+5.4%+6.5%16.6%
GILDGilead Sciences, Inc.LTM Jun 2026$6.07B USD+2.7%+5.2%19.9%
Peer median (excluding GILD) —+7.0%+6.5%18.3%

Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.31B27.28B27.12B28.75B29.44B
Cost of Revenue6.6B5.66B6.5B6.25B6.23B
Gross Profit20.7B21.62B20.62B22.5B23.21B
Gross Margin75.8%79.3%76.0%78.3%78.8%
Research & Development4.6B4.98B5.72B5.91B5.8B
Selling, General & Admin5.25B5.67B6.09B6.09B5.71B
Operating Expenses10.79B14.29B13.01B20.84B11.51B
Depreciation & Amortization2.05B2.1B2.69B2.77B2.76B
EBITDA11.33B8.85B10.5B4.43B13.58B
EBITDA Margin41.5%32.4%38.7%15.4%46.1%
Operating Income9.92B7.33B7.61B1.66B11.7B
Operating Margin36.3%26.9%28.0%5.8%39.7%
Interest Income0106M376M281M349M
Interest Expense1B935M944M977M1.02B
Other Income / Expenses(1.64B)(1.52B)(746M)(972M)(1.91B)
Income Before Tax8.28B5.81B6.86B690M9.8B
Pre-Tax Margin30.3%21.3%25.3%2.4%33.3%
Income Tax Expense2.08B1.25B1.25B211M1.29B
Net Income6.23B4.59B5.67B480M8.51B
Net Margin22.8%16.8%20.9%1.7%28.9%
EPS (Basic)4.963.664.540.386.84
EPS (Diluted)4.933.644.500.386.78
Weighted Avg Shares1.26B1.26B1.25B1.25B1.24B
Weighted Avg Shares (Diluted)1.26B1.26B1.26B1.26B1.26B

Gilead Sciences, Inc.

NASDAQ:GILD

Intrinsic Alpha fair value

Locked

Current Price

$168.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.